HUP0401560A2 - Terápiás kötőmolekulák - Google Patents

Terápiás kötőmolekulák

Info

Publication number
HUP0401560A2
HUP0401560A2 HU0401560A HUP0401560A HUP0401560A2 HU P0401560 A2 HUP0401560 A2 HU P0401560A2 HU 0401560 A HU0401560 A HU 0401560A HU P0401560 A HUP0401560 A HU P0401560A HU P0401560 A2 HUP0401560 A2 HU P0401560A2
Authority
HU
Hungary
Prior art keywords
ser
asn
amino acid
acid sequence
tyr
Prior art date
Application number
HU0401560A
Other languages
English (en)
Inventor
Gregorio Aversa
Frank Kolbinger
José M. Carballido Herrera
András Aszódi
José W. Saldanha
Bruce M. Hall
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0401560A2 publication Critical patent/HUP0401560A2/hu
Publication of HUP0401560A3 publication Critical patent/HUP0401560A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgya kötőmolekula, mely legalább egy antigénkötő helyettartalmaz, ami sorban tartalmazza a CDR1, CDR2 és CDR3 hipervariábilisrégiókat, az említett CDRl aminosav-szekvenciája Asn-Tyr-Ile-Ile-His(NYIIH), az említett CDR2 aminosav-szekvenciája Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Gku-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) ésaz említett CDR3 aminosav-szekvenciája Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); és tartalmazhatja még egymás után a CDR1', CDR2'és CDR3' hipervariábilis régiókat, az említett CDR1' aminosav-szekvenciája Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-lle Gln(RASQNIGTSIQ), az említett CDR2' aminosav-szekvenciája SerSer-Ser-Glu-Ser-Ile-Ser (SSSESIS) és az említett CDR3' aminosavszekvenciája Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), mely például egy kimérahumanizált antitest lehet, ami gyógyszerkészítményként használhatófel. Ó
HU0401560A 2001-02-12 2002-02-11 Therapeutic binding molecules HUP0401560A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0103389.3A GB0103389D0 (en) 2001-02-12 2001-02-12 Organic compounds
PCT/EP2002/001420 WO2002072832A2 (en) 2001-02-12 2002-02-11 Therapeutic binding molecules

Publications (2)

Publication Number Publication Date
HUP0401560A2 true HUP0401560A2 (hu) 2004-11-29
HUP0401560A3 HUP0401560A3 (en) 2012-09-28

Family

ID=9908539

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401560A HUP0401560A3 (en) 2001-02-12 2002-02-11 Therapeutic binding molecules

Country Status (26)

Country Link
US (1) US20040096901A1 (hu)
EP (1) EP1421191B1 (hu)
JP (2) JP2004533816A (hu)
KR (1) KR100752029B1 (hu)
CN (1) CN100529074C (hu)
AR (1) AR035539A1 (hu)
AT (1) ATE526409T1 (hu)
BR (1) BR0207151A (hu)
CA (1) CA2437963A1 (hu)
CZ (1) CZ20032129A3 (hu)
EC (1) ECSP034714A (hu)
ES (1) ES2374554T3 (hu)
GB (1) GB0103389D0 (hu)
HK (1) HK1071769A1 (hu)
HU (1) HUP0401560A3 (hu)
IL (1) IL157136A0 (hu)
MX (1) MXPA03007197A (hu)
NO (1) NO20033549L (hu)
NZ (1) NZ548865A (hu)
PE (1) PE20020871A1 (hu)
PL (1) PL369516A1 (hu)
RU (2) RU2328506C2 (hu)
SK (1) SK10082003A3 (hu)
TW (1) TWI332524B (hu)
WO (1) WO2002072832A2 (hu)
ZA (1) ZA200305911B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050069538A1 (en) 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
MY143963A (en) * 2003-09-18 2011-07-29 Novartis Ag Therapeutic binding molecules
WO2006081620A1 (en) 2005-02-02 2006-08-10 Newsouth Innovations Pty Limited Cd4+ cd25+ t-cells activated to a specific antigen
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US7855057B2 (en) * 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
WO2008014555A1 (en) 2006-08-02 2008-02-07 Newsouth Innovations Pty Limited Method of identifying cd4+cd25+ t cells activated to an antigen which express cd8
KR20100035643A (ko) * 2007-06-05 2010-04-05 노파르티스 아게 성숙 수지상 세포에서의 허용유발 표현형의 유도
IN2012DN02333A (hu) * 2009-10-16 2015-08-21 Dow Agrosciences Llc
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
EP2502631A1 (en) 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immune suppressor and its use
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3026060A1 (en) 2014-11-26 2016-06-01 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for CD45R0
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
IL301859A (en) 2020-10-15 2023-06-01 UCB Biopharma SRL Binding molecules for CD45 multimerization

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
HU221001B1 (hu) * 1994-03-17 2002-07-29 Merck Patent Gmbh. Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok
JPH09191886A (ja) * 1996-01-19 1997-07-29 Asahi Breweries Ltd ヒト高親和性ＩｇＥ受容体に対するヒト型化抗体、半キメラ抗体およびキメラ抗体

Also Published As

Publication number Publication date
JP2004533816A (ja) 2004-11-11
PL369516A1 (en) 2005-04-18
ES2374554T3 (es) 2012-02-17
ECSP034714A (es) 2003-09-24
GB0103389D0 (en) 2001-03-28
US20040096901A1 (en) 2004-05-20
KR100752029B1 (ko) 2007-08-28
JP2009034108A (ja) 2009-02-19
HUP0401560A3 (en) 2012-09-28
NO20033549L (no) 2003-10-10
RU2328506C2 (ru) 2008-07-10
WO2002072832A2 (en) 2002-09-19
EP1421191A2 (en) 2004-05-26
RU2003126168A (ru) 2005-03-10
EP1421191B1 (en) 2011-09-28
RU2405790C2 (ru) 2010-12-10
BR0207151A (pt) 2004-10-05
AR035539A1 (es) 2004-06-02
NO20033549D0 (no) 2003-08-11
NZ548865A (en) 2008-03-28
WO2002072832A3 (en) 2004-03-25
HK1071769A1 (en) 2005-07-29
RU2008100239A (ru) 2009-07-20
CZ20032129A3 (cs) 2003-11-12
KR20040036684A (ko) 2004-04-30
TWI332524B (en) 2010-11-01
ZA200305911B (en) 2004-06-28
CN1551919A (zh) 2004-12-01
PE20020871A1 (es) 2002-11-11
CA2437963A1 (en) 2002-09-19
IL157136A0 (en) 2004-02-08
CN100529074C (zh) 2009-08-19
MXPA03007197A (es) 2003-12-04
ATE526409T1 (de) 2011-10-15
SK10082003A3 (sk) 2004-03-02

Similar Documents

Publication Publication Date Title
HUP0401560A2 (hu) Terápiás kötőmolekulák
NO20061681L (no) Terapeutiske bindingsmolekyler
HRP20181069T1 (hr) Antagonistička protutijela na il-17
HRP20020693B1 (en) HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID Abeta PEPTIDE
CY1124289T1 (el) Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7
HUP0301477A2 (hu) A humán MCP-1 molekula elleni antitestek
GEP20074222B (en) Antibodies to cd40
RS54088B1 (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
RS51468B (en) COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137)
AR035581A1 (es) Anticuerpos para il-1beta humana
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
HUP0104604A2 (hu) CTLA-4 elleni humán monoklonális ellenanyagok
BR0109549A (pt) Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal
CY1107785T1 (el) Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος
WO2022032023A3 (en) Il23r binding molecules and methods of use
TH53886A (th) แอนติบอดี้ต่อ il-1b ในมนุษย์
TH53886B (th) แอนติบอดี้ต่อ il-ib ในมนุษย์
TH123607A (th) โมโนโคลนัลแอนติบอดี il-4 ในมนุษย์

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees